GlobeImmune Inc. intends to offer 5 million shares at $11 to $13 in its planned initial public offering, it indicated in a securities filing Wednesday.
The Louisville-based pharmaceutical company is working on drugs to treat infectious diseases and cancers. GlobeImmune has said it plans to use proceeds from the IPO to fund clinical trials and for potential manufacturing.
GlobeImmune has filed to have its stock listed as “GBIM” on the Nasdaq Global Market.
The company has not announced a date for the offering.